Clinical trials: Neoplasms, Pharyngeal
Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer.
- Conditions
- Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- NCT05075980
- Testing
- Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 174 people
- Sponsor
- Mayo Clinic
Nasopharyngeal Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted treatment in high-risk locoregionally advanced…
- Trial name
- NCT04605562
- Testing
- GP+DDP, Palbociclib, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers
Cancers of the upper aerodigestive tract (UADT) are frequently treated with external beam radiotherapy, either alone or in combination with chemotherapy.
- Trial name
- BaReTox (NCT07413627)
- Testing
- Coplanar External Beam Radiotherapy, Non-Coplanar External Beam Radiotherapy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Georges Francois Leclerc
Nasopharyngeal Carcinoma
Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients
Malnutrition is very common in locally advanced nasopharyngeal carcinoma(NPC) patients undergoing current chemoradiotherapy (CRT) due to dysphagia, mucositis, nausea and other treatment-related problems.
- Trial name
- NCT02776124
- Testing
- Healing Elements,Methuselah Medical Technology
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Otitis Media With Effusion After Nasopharyngeal Carcinoma
A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPC
The primary purpose of this study is to compare balloon Eustachian tuboplasty (BET) combined with tympanostomy tube insertion and simply tympanostomy tube insertion in the treatment of otitis media with effusion (OME) in…
- Trial name
- NCT05449184
- Testing
- Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion, Tympanostomy Tube Insertion
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma (NPC)
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
To explore the efficacy and safety of reduced-dose radiotherapy combined with concurrent chemotherapy and immunotherapy in stage Ⅳa (AJCC 8th,) locally advanced nasopharyngeal carcinoma patients who are sensitive to induction…
- Trial name
- NCT07328841
- Testing
- Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy
- Where
- 12 sites in China
- Volunteers
- 456 people
- Sponsor
- Ming-Yuan Chen
Esophagus Cancer
Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.
To compare the treatment of gullet cancer with radiotherapy alone and assess the advantage and toxicity of adding chemotherapy. The hypothesis to be tested is as follows: That the addition of chemotherapy to a short course of…
- Trial name
- NCT00193882
- Testing
- Cisplatin, Radiotherapy, 5-Fluorouracil
- Where
- 25 sites in Australia, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Nasopharyngeal Carcinoma
Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03932266
- Testing
- Endostar, Cisplatin, Docetaxel
- Volunteers
- 73 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Trial name
- NCT00003251
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Illinois Chicago
Nasopharyngeal Carcinoma
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
This trial plans to enroll patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT05097209
- Testing
- Camrelizumab, Gemcitabine, Induction Cisplatin
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Wei Jiang
Oropharynx Cancer, Radiotherapy; Complications
Adaptive RadioTherapy for OroPharynx Cancer
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to…
- Conditions
- Oropharynx Cancer, Radiotherapy; Complications, Radiotherapy Side Effect, Dysphagia
- Trial name
- ART-OPC (NCT04901234)
- Testing
- Standard radiotherapy +/- chemotherapy, Experimental radiotherapy +/- chemotherapy
- Where
- 2 sites in Australia, Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
This phase Ib/II trial studies the side effects and how well stereotactic body radiation therapy and durvalumab with or without tremelimumab before surgery work in treating participants with human papillomavirus positive…
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive
- Trial name
- NCT03618134
- Testing
- Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Squamous, Squamous Cell Carcinoma
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
This study evaluates the combination of BYL719, cisplatin and cetuximab as induction chemotherapy prior to minimally-invasive transoral surgery (TORS or TLM) and selective lymph node dissection (SLND), followed by risk-adapted…
- Conditions
- Carcinoma, Squamous, Squamous Cell Carcinoma, Oropharyngeal Neoplasms, Oropharyngeal Cancer
- Trial name
- NCT02298595
- Testing
- cisplatin, Cetuximab, BYL719
- Sponsor
- Julie E. Bauman, MD, MPH
Nasopharyngeal Carcinoma
Molecular Mechanism of Nasopharyngeal Carcinoma
EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses.
- Trial name
- NCT00155181
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse.
- Trial name
- NCT07129772
- Testing
- Gemcitabine (GEM), Cisplatin, PEMBROLIZUMAB (alone or when added to a regimen above)
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- The University of Hong Kong
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
This is a phase II clinical trial. The purpose of this study is to determine the feasibility of deescalating chemoradiation treatment based on mid-treatment tumor response determined by rapid nodal shrinkage and clearance of…
- Trial name
- NCT03215719
- Testing
- Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 202 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.
- Trial name
- NCT04014738
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03840421
- Testing
- gemcitabine and cisplatin, cisplatin and fluorouracil, IMRT
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients.
- Trial name
- NCT05724355
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.